U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07483801) titled 'DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies' on Feb. 03.
Brief Summary: What is the research question? Semaglutide and tirzepatide cause weight loss and blood pressure reduction. However, weight loss only partially explains the blood pressure reduction. Based on previous studies, there might be direct effects in the cardiovascular system. In forearm blood flow studies, semaglutide and tirzepatide will be infused into the brachial artery to investigate their effects on the function of blood vessels. In systemic studies, semaglutide and tirzepatide will be infused into systemic circulation...